Introduction
cancer, tumor, tumors
TUMOR, CANCER, DNA DAMAGE, SOLID TUMORS, TUMORS
Although immunotherapy has become a powerful weapon for a wide variety of cancer types, its benefit in the overall population is extremely low. Developing effective immune-combination therapy is a potential strategy to benefit a wider range of patients, especially those who have failed standard therapies.Stereotactic body radiotherapy (SBRT) is a classical and effective locoregional therapy for cancer. In addition to directly causing DNA damage in tumor cells, it also stimulates tumor-specific antigens release, thereby enhancing the antitumor immune response (Nowadays, nanotechnology combined with RT and immunotherapy arises a novel pathway for boosting cancer therapy effect. Liposomal irinotecan is a liposomal formulation of irinotecan, which is one of the well-known chemotherapeutic agents with radiosensitizing property. Liposomes have protective effect on encapsulated drugs and can specifically deliver drugs to tumors owing to enhanced permeability and retention effect (Moreover, preclinical and clinical studies have shown that radiotherapy has a synergistic effect with immunotherapy Based on the abovementioned interactions and synergy, a multi-modal approach combining radiotherapy with liposomal irinotecan, anti-angiogenic therapy, and immunotherapy is a promising therapeutic strategy. To our best knowledge, no clinical trials have investigated this pattern of combination treatment. Herein, we present our phase II study of SBRT with liposomal irinotecan, camrelizumab, and anti-angiogenic therapy for patients with advanced solid tumors who have failed or have no available standard therapy or lack of systemic therapy.